麻豆传媒

Erica Ollmann Saphire, Ph.D. serves as President and CEO of the La Jolla Institute for Immunology. She is one of the world’s leading experts in pandemic and emerging viruses, such as Ebola, Marburg and Lassa. Dr. Saphire directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), an NIH-funded Center of Excellence in Translational Research. The VIC unites 43 previously competing academic, industrial and government labs across five continents to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Dr. Saphire's research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for developing antibody-based treatments. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa.
Dr. Saphire is the recipient of numerous accolades and grants, including the Presidential Early Career Award in Science and Engineering presented by President Obama at the White House; the Gallo Award for Scientific Excellence and Leadership from the Global Virus Network; young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, American Society for Biochemistry and Molecular Biology, and the MRC Centre for Virus Research in the United Kingdom; the Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. Dr. Saphire has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from the German research foundation, Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy.
Dr. Saphire received a B.A. in biochemistry and cell biology and ecology and evolutionary biology from Rice University in Houston, Texas, and a Ph.D. in molecular biology from Scripps Research. She stayed on at Scripps Research as a Research Associate to conduct postdoctoral research and rose through the ranks to become a Professor in the Department of Immunology and Microbiology. In early 2019, Dr. Saphire joined La Jolla Institute for Immunology to establish a molecular imaging facility for cryo-electron microscopy (cryo-EM) at the Institute. The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate.

Dr. Brian Anderson is a Harvard-trained physician-scientist, innovator, and digital health expert. Dr. Anderson鈥檚 focus is on the use of information technology in support of emerging clinical decision support (CDS) models and the provision of safe, effective, patient-centered care. 
While at Athenahealth, where he led the Informatics Department, Dr. Anderson launched a new model of CDS leveraging Artificial Intelligence (AI). He has served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). 
At MITRE, Dr. Anderson works on mCODE, a standardized data language and interoperability model for cancer research and treatment, as well as architecting, implementing, and analyzing health information systems for the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS), and the Department of Veterans Affairs (VA). He also sits on the ONC鈥檚 Health Information Technology Advisory Committee.
Dr. Anderson has written in the Journal of Precision Medicine and spoken at the Precision Medicine Summit and HIMSS19. 

Ho-Fung Hung is a professor of Political Economy at the Johns Hopkins University's Sociology Department and the Paul H Nitze School of Advanced International Studies. His scholarly interest includes global political economy, protest, nation-state formation, social theory, and East Asian Development. He received his bachelor's degree from the Chinese University of Hong Kong, his master's degree from SUNY-Binghamton, and his doctorate in Sociology from Johns Hopkins. Prior to joining the Hopkins faculty, Hung taught at the Indiana University-Bloomington.

Ho-fung Hung is  the author of the award-winning Protest with Chinese Characteristics (2011) and The China Boom: Why China Will not Rule the World (2016), both published by Columbia University Press. His articles have appeared in the American Journal of Sociology, the American Sociological Review, Development and Change, Review of International Political Economy, Asian Survey, and elsewhere. His research publications have been translated into seven different languages, and are recognized by awards from five different sections of the American Sociological Association, Social Science History Association, and the World Society Foundation of Switzerland. His analyses of the Chinese political economy and Hong Kong politics have been featured or cited in The New York Times, The Financial Times, The Wall Street Journal, Bloomberg 麻豆传媒, BBC 麻豆传媒, Die Presse (Austria), The Guardian, Folha de S. Paulo (Brazil), The Straits Times (Singapore),  Xinhua Monthly (China), People鈥檚 Daily (China), among other publications.

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center in Seattle. For more than four decades, he has led some of the most significant advances in medicine, including the development of safe and effective antivirals for herpes, HIV and hepatitis infections. An international expert in the design and testing of vaccines, he is helping to formulate a global, strategic response to COVID-19.

Earlier this year, he responded to the sudden emergence of COVID-19 by redirecting his energies to speed the development of antiviral medications and vaccines against SARS-CoV-2, the virus responsible for the pandemic. He is building strategic collaborations among academic institutions, government health leaders and the pharmaceutical industry to test future COVID-19 vaccines and find ways to manufacture and distribute enough doses to immunize as many as 4 billion people.

Dr. Corey is drawing on his expertise as a co-founder, in 1998, of the HIV Vaccine Trials Network. Headquartered at Fred Hutch in Seattle, it is the world鈥檚 largest publicly funded collaboration focused on development of vaccines to prevent HIV/AIDS.

Dr. Corey's teaching and mentoring interests include virology, viral immunology and development of novel therapies for viral infections. His current research projects include:

- Spatial and functional characterization of tissue resident immune responses at the site of herpesvirus or HIV infection
- Development of immunotherapies for HSV and HIV infection; including CAR T cells for treatment for HIV infection
- Spatial dynamics and function of adoptively transferred or vaccine induced T cells
- Characterization of tissue-based memory B cells and the role antibody effector responses play in chronic viral infections
- Use of monoclonal antibodies for the prevention of viral infections

In addition to his role as president and director emeritus at Fred Hutch, Dr. Corey is a member of the Center's Vaccine and Infectious Disease, Clinical Research, and Public Health Sciences Divisions.  He is also a Professor, Medicine and Laboratory Medicine at the University of Washington, and Principal Investigator at the HIV Vaccine Trials Network (HVTN). 

Joshua LaBaer is renowned for his work in proteomics and developing biomarker diagnostics. He leads ASU's COVID-19 research efforts. 

As executive director of the Biodesign Institute, his work emphasizes that multidisciplinary factors culminate to disease, suggesting personalized therapies and unique biomarker analysis. His team uses arrays to assess how programmable a protein is. This work also spans into epigenetics, and the capacity to modulate the activity of these proteins.

LaBaer was the founder and director of Harvard's Institute of Proteomics and a chairman of the Virginia G. Piper Center for Personalized Diagnostics. He is an associate editor of the Journal of Proteome Research, a member of the National Cancer Institute's Board of Scientific Advisors, chair of the Early Detection Research Network Steering Committee and recent president of the U.S. Human Proteome Organization.

Jill Messing specializes in intervention research. As associate professor in the School of Social Work, her research areas include intimate partner violence, risk assessment, domestic homicide and femicide, criminal justice-social service collaborations and evidence-based practice. Messing is the Principal Investigator on the National Institute of Justice funded Oklahoma Lethality Assessment Study, which examines the effectiveness of the Lethality Assessment Program across 7 jurisdictions in Oklahoma, and the co-Investigator on the National Institute of Mental Health funded study The Use of Computerized Safety Decision Aids with Victims of Intimate Partner Violence.

Mara Aspinall is an expert in biomedical diagnostics, biomedicine and medical diagnostic devices.

She is a professor of practice in the College of Health Solutions and the co-founder of the Biomedical Diagnostics program within the college.

Throughout her career, Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine.

In addition to her position at ASU, Aspinall is the co-founder and managing director of BlueStone Venture Partners and the managing director of Health Catalysts Group.

Dragan Boscovic is an expert in machine learning, cognitive networks and symbiotic relations.

He is the director of ASU鈥檚 Blockchain Research Lab and is the technical director of ASU鈥檚 Center for Assured and Scalable Data Engineering.

Boscovic, a research professor in the School of Computer Information and Decision Systems Engineering, has experience in numerical electromagnetics, wireless systems and IP networks, hardware and software architectures, blockchain data structures and data analytics.

He the CEO of VizLore, LLC, an information technology and services company focusing on smart cities, smart energy/grid and smart health applications. He served as a Motorola research director for nearly 20 years.

A Motorola research director for nearly 20 years, Boscovic has amassed 22 patents and published papers on diverse topics, such as data analytics for mobile services, consumer-centric mHealth and eHealth solutions and autonomic information and communications technology networks.

Efrem Lim is an expert in viruses, biomedicine, microbiology and molecular biology.

He is a virologist and an assistant professor in the School of Life Sciences, and the Biodesign Center for Fundamental and Applied Microbiomics.

Lim's research focuses on viromes, microbiomes and the SARS-CoV-2 viral strain.

Professor Lim created the "Lim Lab" at ASU which integrates molecular virology and bioinformatics approaches in clinical cohorts.